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INTRODUCTION 
Arthritis, which is a chronic joint disease, 
has been known for years as a potentially crippling 
disease; but in the main, it has remained of unknown 
etiology. In most cases the treatment is symptomatic 
and must be tailored to each individual's needs. 
It is for this reason that a complete evalu-
ation is necessary including a history, physical 
examination, appropriate laboratory studies, and 
roentgenograms. This affords a knowledge of the 
patients's general condition, as 1Nell as any asso-
ciated or complicating disorders. The entire patient 
must be considered when initiating therapy. 
Treatment of arthritis is primarily sympto-
matic, aimed'at reduction of pain, reduction of 
inflammation, adequate rest, and physical therapy. 
If pain and inflammation reduction can be maintained, 
the rest and physical therapy might naturally follow. 
Such local measures as splintage, heat, rest, and 
counter-irritation, all play their part in this 
reduction of pain and inflammation. 
Aspirin has remained the most important drug 
in the treatment of arthritis for the past 25 years. 
Th.ere are, however, about 25% of arthritis patients 
who cannot tolerate aspirin, at least not in anal-
gesic doses. Intolerance to aspirin is usually 
due to gastric irritation or hypersensitivity. (6) 
'rfuen aspirin has failed, phenylbutazone com-
pounds, also having both analgesic and antiphlogistic 
effects, may be used. There are many more untoward 
effects, however, including salt retention, gastric 
irritation, reduction of bleeding time, allergic 
rashes, and agranulocytosis. Phenylbutazone com-
pounds are usually given for a trial period of one 
week, if none of the preceding symp~oms have been 
present with less toxic analgesics. If, at the 
end of one week, improvement is not marked, the 
drug is discontinued.(6) 
Steroids, primarily prednisone and prednisolone, 
may be indicated in severe or difficult arthritis. 
They should not be used intermittently or alternated 
with aspirin or phenylbutazone, according to Dr. 
Kersley.(6) Side effects of steroids, of course, 
include salt retention, hypertension and Cushinoid 
appearance. Steroids are contraindicated in patients 
with associated peptic ulcer, severe hypertension, 
diabetes mellitus, or recent psychoses. In cases 
such as these, gold therapy may be considered. The 
(2) 
effects of gold therapy are less certain and slower 
but the benefits are usually longer and side effects 
less disturbing.(4) 
The majority of this paper will be concerned 
with a double-blind clinical evaluation of a new 
analgesic agent and its effect on the chronic pain 
of arthritis.·· The new drug is known only by the 
code name of SQ 10,269.' 
CHEMISTT{Y AND PH/\!{lI-Lt\COLCGY 
Chemically, 10,269 is 2-Ethoxy-N-methyl-N-
[2-( methylphenethylamino )ethyl] -2, 2-diphenylacetamide 
hydrochloride. The structural formula is as follows: 
Hel 
10,269 (8, p. 73) 
It is classed as a basic amide of diphenyl-
acetic acid. The parent compound, with similar 
analgesic properties, is 4773. As an analgesic 
agent, Sf~ 10,269 is considered to be about 1.5 times 
as effective as SQ 4773. Chemically, 4773 has a 
methyl group in place of the phenylethyl group on 
the amino nitrogen, as sho~n at top of following 
page. (7) 
(3) 
SQ 10,269 SO 4773 
SQ 10,269 is a white, odorless, tasteless, 
crystalline powder, which dissolves about 1.0% in 
water, forming a solution with a pH of 3.5. It is 
very soluble in methanol and chloroform, and is 
insoluble in ether. It is stable on exposure to 
air, light, and temperatures up to 60°C.(8p.73) 
In a series of experiments using mice, SQ 10,269 
was found to be about 1.3 times as potent as mep-
eridine and about equal to codeine sulfate and 
propoxylene. Clinically, SQ 10,269 was compared 
to codeine sulfate. The experimental pain thresh-
hold produced by the electrical stimulation of a 
metallic filling in a vital tooth was the bas.is for 
the comparison. It was found that 100 mg. of SQ 10,269 
had the equivalent analgesic effect of 64 mg. of 
codeine and produced a more enduring response. The 
degree of pain relief with SQ 10,269 has been 
directly proportional to the dose. The higher the 
dose, however, the higher the incidence of side 
effects. Drowsiness, vertigo, nausea, and vomiting 
have been the most prominently reported side effects 
(4) 
thus far. No untoward effects on the liver, kidneys, 
or hematopoietic system have been noted clinically. 
Patients, who have been placed on the drug for as 
long as fourteen weeks have shown no evidence of 
toxicity or physical dependence. 
Vomiting has been noted in dogs with high doses 
of SQ 10,269. All dogs vomited within a few minutes 
when in the fasting state and given a dosage of 
160 mg./Kg. However, in the non-fasting state, fifty 
per cent of the animals retained doses as large as 
320 mg./Kg. After retained doses of this magnitude, 
no effects were observed on the respiratory rate, 
blood pressure, heart rate, electrocardiogram, or 
pupillary diameter. 
The spontaneous motor activity decreased in 
mice when given either SQ 10,269 or codeine sulfate. 
The decrease was inversely related to the dose. The 
smaller doses caused a greater decrease in activity_ 
SQ 10,269 tolerance has been demonstrated to 
occur at about the same rate as that of meperidine. 
Rats developed tolerance to either drug after about 
15-20 days. Tolerance to SQ 10,269 did not show cross 
tolerance to meperidine, whereas tolerance to mep-
eridine did show reciprocal tolerance to SQ 10,269. 
(5) 
Complete withdrawal for 21 days restored the original 
effect with either drug. 
The median lethal dose (LD50) of SQ 10,269 
varied with the concentration of the drug. The 
lower concentrations were more lethal than the 
higher concentrations, indicating that the lower 
concentrations were more rapidly or completely ab-
sorbed from,the g~strointestinal tract. The median 
lethal oral dose was estimated to be 325 mg./Kg. 
Two of three rats died when given 350 mg./Kg. as a 
2% solution, wher~as only one of three died when 
given 500 mg./Kg. as a 4% solution. The LD50 of 
intravenously administered SQ 10,269 was 40 ± 1.7 
mg./Kg. 
The effect of chronic ingestion of the drug 
was demonstrated by giving three groups of dogs 
4.5, 14 and 40 mg./Kg., ,respectfully, for 26 weeks. 
All three groups appear,ed alert and healthy through-
out the 26 week period. In the 40 mg./Kg. group, 
there were Bromsulfalein changes and an elevation 
of the 'Serum Glutamic Pyruvic Transaminase levels 
suggestive of depressed liver function. The inter-
mediate and low dose groups demonstrated no abnormal 
laboratory values. Only the dogs that received 40 
(6) 
mg./Kg. showed any pathological changes when sac-
rificed. In these dogs the liver showed moderate 
degeneration evidenced by the following: numerous 
homogeneous eosinophilic bodies in liver cells, 
a few acidophilic bodies, and an increased number of 
double nucleated cells. 
SQ 10,269 is considered to be a non-addicting 
analgesic agent indicated for the relief of all 
types of pain, including post-operative pain and 
pain associated with chronic and recurrent diseases. 
There are no known contraindications to its use. At 
present the dosage is exploratory, pending the outcome 
of further clinical pharmacological trials. The 
dosage originally recommended for this study was 
150 mg. four times daily, but was changed to 150 mg. 
twice daily. The change was requested by the manu-
facturer, apparently due to side effects with the 
higher dosage. 
PURPOSE .. 'ND ME:THOD OF STUDY 
The purpose of this study was to evaluate the 
following: the extent of pain relief, the presence 
and severity of side effects, and the toxicity ,of 
SQ 10,269. 
The patients selected ,vere moderate to severe 
arthritics, and were seen weekly by the author in 
(7) 
the Arthritis Clinic of the University of Nebraska 
College of Medicine. There were five patients class-
ified with osteoarthritis, seven classified with 
rheumatoid arthritis, and one with mixed rheumatoid 
and osteoarthritis. There were two men and eleven 
women, and their ages varied from 33 to 84. Of the 
total of thirteen patients selected, eleven completed 
the study. Two patients dropped out due to intol-
erence to the drug. 
The medications were supplied as buff colored 
gelatin capsules by the Squibb Institute for Medical 
Research. They were labeled only with the codes 
of JEX and JEV. After the study was completed, the 
code was broken and revealed that: 
JEX was SQ 10,269--150 mg. per capsule 
JEV was aspirin----600 mg. per capsule 
Each patient served as his own control in 
this double-blind study. The two codes were alter-
nated every week for a total of one month. The 
patients were given a weeks supply of medication and 
instructed to take one capsule twice daily with 
breakfast and supper. They were to keep a daily 
record of the degree of analgesia, side effects, and 
necessary concomitant analgesia. No patient was 
(8) 
asked specifically about side effects, and those 
recorded were spontaneously expressed by the patient. 
At the beginning of the study and at two week 
intervals dur~ng the study, the following laboratory 
values were checked: cOl:nplete blood count, urin-
alysis, blood urea nitrogen, cephalin cholesterol 
flocculation, alkaline phosphatase, and serum glutamic 
pyruvic transaminase. All prior analgesic medication 
was discontin~ed. All other medications, such as 
steroids, gold, cardiovascular and renal medications, 
were left unchanged, At the conclusion of each 
patient's test series, the original analgesic med-
ication was again reinstated. 
:EVALUATION OF RESULTS 
The patient recorded his own daily report on 
a form similar to the one reproduced in Fig. 1. 
Table 1 is a composite of all the patient report 
forms. 
Degree of relief 
SQ 10,269 
Aspirin 
o 1 234 
3 7 60 41 42 
33 41 49 39 0 
Table 1 
Total 
153 
162 
rfhe code for the degree of relief is as follows: 
(9) 
I"". 
I-' 
o 
'-" 
Patient's Name 
Day of the Week 
Daily Capsule Number 
Pain None 
Relief Slight Moderate 
Almost Complete 
Complete 
Other Drugs 
For Name 
Pain Relief 
Amount 
Remarks 
stud;! Week Number 
First Second Third Fourth Fifth Sixth Seventh 
-.---"-... --'.--.'-.~- .. -... ------ ~~ -
Fig. 1 
0, = None 
1 = Slight 
2 = Moderate 
3 = Almost complete 
4 = Complete 
The total number of SQ 10,269 observations 
should have equaled the total number of aspirin 
observations; however, a few of the patients were 
unable to complete their entire weekly dosage due to 
intolerence of one kind or another. 
The effectiveness was compared by using the 
method of Cass, Frederik and Bartholomay. (2) This 
was done by employing the following formula: 
Number of observations times rating 
Total number of observations 
The average effectiveness of SQ 10,269 would then 
be as follows: 
3xO + 7xl + 60x2 + 41x3 + 42x4 
153 
= 2.7 
And the average effectiveness of aspirin would be: 
33xO + 41xl + 49x2 + 39x3 + Ox4 
= 1.6 
162 
The means obtained above were compared stat-
istically. The standard deviation for SQ 10,269 
was 0.9975 and that for aspirin was 1.0643. The 
standard error of the difference between the two 
(11) 
means was 0.115. This figure divided by the ob-
served difference of 1.1 produced a relative deviate 
of 9.5. This is to say that the possibility of the 
difference between the two means being due to chance 
alone is a figure 9.5 deviations from the mean. The 
p value then is considerably less than 0.001.(1) 
The duration of pain relief with SQ 10,269 was 
reported by most patients to be between five and 
eight hours. 
In compiling the list of side effects, it 
should be remembered that these were spontaneous 
observations of the patient. None of the symptoms 
were asked about or suggested. The following table 
shows the comparison of side effects elicited in 
this study with SQ 10,269 and aspirin. 
The most common side effects were vertigo, 
drowsiness, and nausea, in that order. These are 
the same side effects mentioned as most prominent 
in the literature received from the manufacturer. 
The relative incidence, however, appears to be 
greater in this study. No instances of constipa-
tion were reported; but in experimental studies, 
SQ 10,269 was shown to be more effective than codeine 
in slowing peristalsis. 
(12) 
Side effects SQ 10,269 aspirin 
Nausea 35 1 
Vertigo 66 
° Vomiting 10 0 
Constipation 0 
° Drowsiness 45 7 
Excitement 1 0 
Headache 7 1 
Abdominal cramps 1 0 
Weakness 2 0 
Table 2 
No significant toxic effects were noted from 
the laboratory studies done. Two patients showed 
a' rise from normal in the cephalin flocculation; 
however, an equal number returned to normal after 
an abnormal control. The SGPT rose above normal 
in one patient on one occasion, and rose above the 
control values in several others. The significance 
of these few values is difficult to ascertain, but 
the author feels it is small. 
Sll1.!MARY 
SQ 10,269 is a basic amide derivative of di-
phenylacetic acid. It is a new non-narcotic analgesic 
which has been evaluated in animal experiments and 
is preseptly being studied clinically. It is an 
effective analgesic with a potency equivalent to 
that sf codeine. No toxic effects on hepatic, renal 
(13) 
or hematopoietic systems have been noted. While 
tolerance has been demonstrated to occur, no in-
dications of addiction have been shown. 
This investigative study was conducted in a 
double-blind manner using 150 mg. of SQ 10,269 and 
600 mg. of aspirin. The analgesic activity was 
compared in thirteen moderately severe arthritis 
patients. Each of the medications had the same 
appearance and were alternated w·eekly in each patient 
for a total of four weeks. In this way, each patient 
acted as his own control. 
The composite results showed that SQ 10,269 
was significantly superior to aspirin in the dosages 
used.(p 0.001) The incidence of side effects was 
also significantly higher with SQ 10,269. The 
most frequently noted in this and also in previous 
studies, have been vertigo, drowsiness, nausea, and 
vomiting. 
CONCLUSION 
In conclusion, SQ 10,269 appears to be an 
effective analgesic agent in relieving the pain 
due to moderate to severe arthritis. The side 
effects noted, however, might preclude its popularity. 
It may be that a smaller single dose at more frequent 
(14) 
intervals, may be as effective an analgesic without 
the incidence of side effects. 
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